WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Clinical trials for WARM AUTOIMMUNE HEMOLYTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new WARM AUTOIMMUNE HEMOLYTIC ANEMIA trials appear
Sign up with your email to follow new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Drug access program offers hope for rare blood disorder patients
Disease control TEMPORARILY_NOT_AVAILABLEThis program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC